Crinetics Pharmaceuticals (CRNX) Competitors $29.69 -0.40 (-1.33%) Closing price 04:00 PM EasternExtended Trading$29.87 +0.18 (+0.61%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRNX vs. VRNA, BBIO, BPMC, ELAN, ROIV, GRFS, LEGN, RVMD, RYTM, and RNAShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Crinetics Pharmaceuticals vs. Its Competitors Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Elanco Animal Health Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings. Do insiders and institutionals hold more shares of VRNA or CRNX? 85.9% of Verona Pharma PLC American Depositary Share shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are owned by insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, VRNA or CRNX? Verona Pharma PLC American Depositary Share has higher revenue and earnings than Crinetics Pharmaceuticals. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma PLC American Depositary Share$42.28M211.96-$173.42M-$0.99-106.33Crinetics Pharmaceuticals$1.04M2,688.66-$298.41M-$4.11-7.22 Do analysts recommend VRNA or CRNX? Verona Pharma PLC American Depositary Share presently has a consensus price target of $109.00, suggesting a potential upside of 3.54%. Crinetics Pharmaceuticals has a consensus price target of $68.86, suggesting a potential upside of 131.92%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma PLC American Depositary Share 0 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.15Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has more risk & volatility, VRNA or CRNX? Verona Pharma PLC American Depositary Share has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Does the media prefer VRNA or CRNX? In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than Verona Pharma PLC American Depositary Share. MarketBeat recorded 13 mentions for Crinetics Pharmaceuticals and 8 mentions for Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.50 beat Crinetics Pharmaceuticals' score of 0.12 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma PLC American Depositary Share 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 1 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is VRNA or CRNX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. Verona Pharma PLC American Depositary Share's return on equity of -21.12% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Verona Pharma PLC American Depositary Share-36.62% -21.12% -9.07% Crinetics Pharmaceuticals N/A -32.28%-29.45% SummaryCrinetics Pharmaceuticals beats Verona Pharma PLC American Depositary Share on 9 of the 16 factors compared between the two stocks. Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.80B$2.45B$5.58B$9.81BDividend YieldN/A1.68%4.60%4.11%P/E Ratio-7.2222.0530.2825.72Price / Sales2,688.66484.52388.3180.18Price / CashN/A183.0237.7558.93Price / Book2.394.718.456.01Net Income-$298.41M$31.61M$3.25B$265.06M7 Day Performance6.49%3.93%4.05%2.80%1 Month Performance-10.08%3.32%4.32%1.68%1 Year Performance-42.27%13.53%36.25%29.59% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals3.4178 of 5 stars$29.69-1.3%$68.86+131.9%-40.2%$2.80B$1.04M-7.22210News CoverageEarnings ReportAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.3651 of 5 stars$105.240.0%$109.00+3.6%+293.6%$8.96B$42.28M-106.3030Positive NewsShort Interest ↓BBIOBridgeBio Pharma4.362 of 5 stars$48.24+3.6%$61.35+27.2%+110.7%$8.90B$221.90M-11.79400Insider TradeBPMCBlueprint Medicines0.8586 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ELANElanco Animal Health2.8925 of 5 stars$17.10+2.6%$17.33+1.3%+27.9%$8.28B$4.44B19.899,000Earnings ReportAnalyst ForecastAnalyst RevisionROIVRoivant Sciences2.7277 of 5 stars$11.17-2.8%$16.50+47.7%+5.3%$7.81B$29.05M0.00860Gap DownGRFSGrifols3.7511 of 5 stars$10.60-0.6%$10.30-2.8%+54.4%$7.33B$7.81B9.0623,822Short Interest ↑LEGNLegend Biotech3.745 of 5 stars$36.24-2.1%$73.33+102.4%-35.3%$6.80B$627.24M-61.422,609News CoveragePositive NewsEarnings ReportAnalyst ForecastRVMDRevolution Medicines3.729 of 5 stars$34.70-0.9%$68.82+98.3%-16.2%$6.54B$11.58M-7.71250Analyst RevisionRYTMRhythm Pharmaceuticals3.7635 of 5 stars$94.31+2.5%$101.57+7.7%+112.9%$6.11B$130.13M-31.33140News CoveragePositive NewsInsider TradeAnalyst RevisionRNAAvidity Biosciences2.913 of 5 stars$45.75-1.2%$67.00+46.4%+3.0%$5.96B$10.90M-15.25190Upcoming EarningsAnalyst Revision Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share Competitors BridgeBio Pharma Competitors Blueprint Medicines Competitors Elanco Animal Health Competitors Roivant Sciences Competitors Grifols Competitors Legend Biotech Competitors Revolution Medicines Competitors Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRNX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access